Funding for this research was provided by:
International Breast Cancer Research Foundation (BCRF-17-069)
Clinical Trial Center, China Medical University Hospital (CMU109-YT-06)
Article History
Received: 4 September 2022
Accepted: 19 October 2022
First Online: 25 October 2022
Declarations
:
: Not applicable.
: Not applicable.
: Overcoming PARP inhibitor resistance through the combination of RTK inhibitors and PARPi, are covered in the provisional patent UTSC.P1450US.P1. The provisional patent (UTSC.P1450US.P1) titled “Combinational Therapy Targeting PARP1 and RTK” was invented by M.-C.H., M.-K.C., and Y.-Y.C. and filed by The University of Texas.